Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Breast Care (Basel, Switzerland)
|
September 28, 2020
ASCO 2020
Rupert Bartsch, Veronique Dieras, Javier Cortes, et al.
Breast Care (Basel, Switzerland)
|
March 15, 2021
Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8-11, 2020
Volkmar Müller, Veronique Dieras, Fatima Cardoso, et al.
American Journal of Clinical Oncology
|
April 7, 2007
QTc monitoring during a phase I study: experience with SR271425
Jean-Charles Soria, Veronique Dieras, Veronique Girre, et al.
Breast Cancer Research and Treatment
|
November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Investigational New Drugs
|
October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer
Christian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
British Journal of Cancer
|
February 22, 2017
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Richard H Wilson, Tr Jeffry Evans, Mark R Middleton, et al.
Future Oncology (London, England)
|
May 11, 2019
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases
Debu Tripathy, Sara M Tolaney, Andrew D Seidman, et al.
Anticancer Research
|
March 19, 2017
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
Veronique Dieras, Simona Pop, Frederique Berger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2017
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study
Christophe Massard, Isabelle Borget, Françoise Farace, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
Stephen Johnston, John Pippen, Xavier Pivot, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Breast Care (Basel, Switzerland)
|
September 28, 2020
ASCO 2020
Rupert Bartsch, Veronique Dieras, Javier Cortes, et al.
Breast Care (Basel, Switzerland)
|
March 15, 2021
Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8-11, 2020
Volkmar Müller, Veronique Dieras, Fatima Cardoso, et al.
American Journal of Clinical Oncology
|
April 7, 2007
QTc monitoring during a phase I study: experience with SR271425
Jean-Charles Soria, Veronique Dieras, Veronique Girre, et al.
Breast Cancer Research and Treatment
|
November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Investigational New Drugs
|
October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer
Christian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
British Journal of Cancer
|
February 22, 2017
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Richard H Wilson, Tr Jeffry Evans, Mark R Middleton, et al.
Future Oncology (London, England)
|
May 11, 2019
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases
Debu Tripathy, Sara M Tolaney, Andrew D Seidman, et al.
Anticancer Research
|
March 19, 2017
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
Veronique Dieras, Simona Pop, Frederique Berger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2017
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study
Christophe Massard, Isabelle Borget, Françoise Farace, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
Stephen Johnston, John Pippen, Xavier Pivot, et al.
Page
of 3